The global zoonotic disease treatment market was valued at around US$ 36.9 Billion at the end of 2021. The market is projected to register a 5.9% CAGR and top a valuation of US$ 69.2 Billion by 2032.
“Crowded settings, poor hygiene, fluctuating temperatures and habitats, livestock farming, and a lack of awareness are foreseen aspects supporting the growth of the zoonotic disease treatment market.”
Animals often carry dangerous pathogens that can infect humans and produce zoonotic diseases, also called zoonoses. A sort of unexpected illness known as zoonosis is spread from both animals to humans and from humans to animals. Zoonotic diseases are brought on by pathogenic microorganisms such as bacteria, fungi, parasites, and viruses.
Mild to severe illnesses, even deaths can be led on by these infections in both humans and animals. Some zoonotic diseases include tuberculosis, rabies, hepatitis, and relapsing fever. Depending on the zoonotic disease, animals can occasionally seem healthy even when they are harboring pathogens that can make people sick.
| Attributes | Details |
|---|---|
| Zoonotic Disease Treatment Market Value in 2021 | US$ 36.9 Billion |
| Zoonotic Disease Treatment Market Value in 2032 | US$ 69.2 Billion |
| Zoonotic Disease Treatment Market CAGR (2022 to 2032) | 5.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Population growth, migration, and rapid urbanization are all factors that could lead to the emergence of new zoonotic diseases in the future. Due to market and production procedures for live food animals, people in urban regions are less familiar with dealing with animals than those in rural settings. The urban population may also reside in overcrowded conditions that aid in the spread of disease.
Increased demand for animal proteins is probably going to result in increased consumption of animal fats, which is going to fuel the market for zoonotic disease treatment. With millions of households owning one or more pets for companionship and entertainment. However, the possibility that some animals may carry pathogens that might infect humans when in contact is anticipated to drive the market for the same.
The zoonotic disease treatment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America is the leading region in the global zoonotic disease treatment market owing to the rising population, higher rate of immigration, and rapid urbanization.
Apart from North America, the European zoonotic disease treatment market is also expected to display lucrative growth in the projected years due to the extensive livestock farming and increased consumption of animal fat in country places.
The East Asian region is predicted to show lucrative growth owing to a lack of access to safe drinking water and adequate sanitation services, which could contribute to the development of zoonotic diseases.
Principal Consultant
Cadila Healthcare Ltd, AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Novartis International AG, Sanofi S.A., BioCryst Pharmaceuticals, Inc, Sun Pharmaceuticals Industries, Ltd.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Disease Type, Drug Class, End User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Cadila Healthcare Ltd; AstraZeneca plc; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Johnson & Johnson; Pfizer Inc.; Novartis International AG; Sanofi S.A.; BioCryst Pharmaceuticals, Inc; Sun Pharmaceuticals Industries, Ltd. |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global zoonotic disease treatment market is anticipated to register a CAGR of 5.9% during the forecast period.
The global zoonotic disease treatment market is projected to be about US$ 69.2 Billion by the end of the year 2032.
Explore Healthcare Insights
View Reports
Zoonotic Disease Treatment Market
